Three biologics targeting interleukin 5 (IL-5) or its receptor (IL-5Rα) are approved for use in patients with severe asthma. In a meta-analysis, Greek scientists have now investigated the clinical response to anti-IL-5/-5Rα biologics in real-world studies and provided insights into the use of these drugs in clinical practice.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)
Diagnosis at an early stage, prognostic classifications and outlook
- Case report: Drug-induced hepatitis
Rare side effect of tirzepatide therapy
- Plea for sex-specific neurology
Migraine in men: underdiagnosed, underestimated, under-researched
- Prurigo nodularis
Retrospective analyses of large data sets from everyday practice
- Public Health
Outpatient care in Switzerland: situation report
- Practice Management
Improved quality of care aims for satisfied patients
- Chemsex - MSM, sex, chrystal meth & co.
Medical and psychosocial perspectives
- Bladder cancer